TY - JOUR
T1 - Induction of ovulation with d-trp6-LHRH combined with purified FSH in patients with polycystic ovarian disease
AU - Ayalon, D.
AU - Ben-David, M.
AU - Wohl, R.
AU - Jaffe, R.
AU - Vagman, I.
AU - Eckstein, N.
AU - Limor, R.
AU - Comaru-Schally, A. M.
AU - Schally, A. V.
PY - 1988
Y1 - 1988
N2 - Seventeen patients with polycystic ovarian disease (PCOD) and evidence of mild or severe ovarian hyperstimulation syndrome (OHSS) during therapy with CC/hCG, FSH/hCG or hMG/hCG were treated with D-Trp6-LHRH until medical gonadectomy was attained. Under the suppressive therapy with the GnRH agonist (GnRHa) ovulation was induced with FSH/hCG. In 15 out of 17 patients, ovulatory cycles were obtained with this new modality of treatment. Seven patients conceived (3 viable pregnancies and 4 early abortions) after the 1st treatment cycle. Fourteen of the 17 patients demonstrated symptoms of mild OHSS which did not require hospitalization. Only 1 patient developed severe OHSS after the combined treatment. Our results suggest that therapy with GnRHa, especially in its delayed release formulation, is effective for the prevention of severe ovarian hyperstimulation in PCOD patients undergoing treatment with menotropins for the induction of ovulation.
AB - Seventeen patients with polycystic ovarian disease (PCOD) and evidence of mild or severe ovarian hyperstimulation syndrome (OHSS) during therapy with CC/hCG, FSH/hCG or hMG/hCG were treated with D-Trp6-LHRH until medical gonadectomy was attained. Under the suppressive therapy with the GnRH agonist (GnRHa) ovulation was induced with FSH/hCG. In 15 out of 17 patients, ovulatory cycles were obtained with this new modality of treatment. Seven patients conceived (3 viable pregnancies and 4 early abortions) after the 1st treatment cycle. Fourteen of the 17 patients demonstrated symptoms of mild OHSS which did not require hospitalization. Only 1 patient developed severe OHSS after the combined treatment. Our results suggest that therapy with GnRHa, especially in its delayed release formulation, is effective for the prevention of severe ovarian hyperstimulation in PCOD patients undergoing treatment with menotropins for the induction of ovulation.
UR - http://www.scopus.com/inward/record.url?scp=0024253109&partnerID=8YFLogxK
U2 - 10.3109/09513598809107655
DO - 10.3109/09513598809107655
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:0024253109
SN - 0951-3590
VL - 2
SP - 319
EP - 330
JO - Gynecological Endocrinology
JF - Gynecological Endocrinology
IS - 4
ER -
